← boardnext 2028-12
OTLC
Oncotelic Inc.distress 6/10 · elevated risk$0.040%today-64% from 52w high
Oncology 1
Lead: Malignant Pleural Mesothelioma · target TGF-b2
Revenue
pre-revenue
Liquidity
$0M
Runway
0.3 yrs
Shares 1y
+2%
Price & events
-50.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
-20.0%
1M
+0.0%
3M
-50.0%
6M
-20.0%
1Y
+33.3%
2Y
-76.5%
5Y
-81.8%
All
Overview
- Market Cap
- $17.78M
- Volume
- 123.90K
- 52 Week Range
- $0.03 – $0.11
- Total Shares
- 444.50M
- Float Shares
- 228.84M
- Short %
- 2.50%
- % Held by Insiders
- 44.70%
- % Held by Institutions
- 0.00%
- RVOL
- 0.45x
- Beta
- -0.27
Pipeline stages · 1 programs
OT-101
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-12 Estimated 50% readout ~2029-01-15 | Phase 2 | OT-101 | Malignant Pleural Mesothelioma | — | not yet recruiting |
| 2026-06-01 | Phase 2/3 | OT-101, mFOLFIRINOX | Pancreatic Ductal Adenocarcinoma | 455 | recruiting |
Catalyst news & presentations · 5
- 2026-05-06partnershipCNS/Nasal assets · Closing of strategic monetization of CNS/Nasal assets with Lunai Bioworks for joint development in biodefense and Alzheimer's disease.PR wire
- 2026-04-02partnershipJoint Development, Manufacturing, and Licensing Agreement with TechForce Robotics for PDAOAI-enhanced GMP robotics platformSEC 8-K
- March 25, 2026conferencedata presentationsecondarySapu Nano presentation at BIO-Europe Spring 2026 introducing Deciparticle platform and clinical pipeline.SEC 8-K
- March 23, 2026conferencedata presentationsecondaryeverolimus · Presentation of everolimus toxicology data at SOT 2026 Annual Meeting.SEC 8-K
- 2024-12-31partnershipExtended binding term sheet with Mosaic ImmunoEngineering for reverse merger to June 30, 2025.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — TGF-b2
- none identified
Recent news
- 2026-07-22Oncotelic Therapeutics, Inc. announced that it has received $0.71184 million in funding - marketscreener.com
- 2026-07-22Oncotelic Therapeutics (OTLC) files Form D for $711,840 Rule 506(b) RSU offering - Stock Titan
- 2026-07-22Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus) - The Manila Times
- 2026-07-22Oncotelic Study Reports Less Gastrointestinal Exposure With IV Everolimus - Stock Titan
- 2026-07-22Oncotelic Announces Peer-Reviewed Publication Validating - GlobeNewswire
- 2026-07-21Oncotelic Therapeutics (OTLC) awards 250 RSUs conditioned on uplisting - Stock Titan
- 2026-07-16Oncotelic Therapeutics Launches AI-Powered Manufacturing Services Platform for Biotech Firms - citybuzz -
- 2026-07-14Oncotelic Therapeutics (OTLC) awards 17,796 RSUs tied to uplisting - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.